revefenacin
Selected indexed studies
- Revefenacin. (, 2012) [PMID:31644224]
- Revefenacin. (, 2006) [PMID:30601616]
- Revefenacin: First Global Approval. (Drugs, 2019) [PMID:30560478]
_Worker-drafted node — pending editorial review._
Connections
revefenacin is a side effect of
Sources
- Revefenacin. (2012) pubmed
- Revefenacin. (2006) pubmed
- Revefenacin: First Global Approval. (2019) pubmed
- Revefenacin (Yupelri) for COPD. (2019) pubmed
- Revefenacin for the treatment of chronic obstructive pulmonary disease. (2019) pubmed
- Revefenacin for the treatment of chronic obstructive pulmonary disease. (2020) pubmed
- Revefenacin: A Once-Daily, Long-Acting Bronchodilator For Nebulized Treatment Of COPD. (2019) pubmed
- Sodium zirconium cyclosilicate, Revefenacin, and Cannabidiol. (2019) pubmed
- Revefenacin, a once-daily, long-acting muscarinic antagonist, for nebulized maintenance therapy in patients with chronic obstructive pulmonary disease. (2021) pubmed
- Safety evaluation of revefenacin at the approved dose in patients with chronic obstructive pulmonary disease: A meta-analysis. (2022) pubmed